S. Roberts

Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma

D. Koh, M. Jenner, M. Blackledge, 2022, Insights into Imaging.

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma

H. Auner, M. Kaiser, M. Garg, 2022, BMJ Open.

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

G. Morgan, G. Cook, D. Meads, 2022, Blood Cancer Journal.

MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

M. Jenner, C. Messiou, G. Pratt, 2021, BMJ Open.

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

R. Houlston, M. Drayson, M. Jenner, 2022, Blood.

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

R. Houlston, M. Drayson, M. Jenner, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial

M. Drayson, M. Jenner, G. Cook, 2021, Clinical Lymphoma Myeloma and Leukemia.

Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial

M. Drayson, S. Faustini, J. Heaney, 2023, British journal of haematology.

Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study

M. Jenner, M. Blackledge, J. Winfield, 2023, Insights into Imaging.